progressive multiple sclerosis

#ACTRIMS2022 ā€“ In New Mouse Model, Evobrutinib Shows Efficacy

Researchers developed a new mouse model that more closely captures a specific type of inflammation characteristic of progressive multiple sclerosis (MS) ā€” and found, in experiments, that treatment with an oral medicationĀ called evobrutinibĀ can lessen disease activity. This new mouse model may help scientists in MS to better study…

MediciNova Announces Update On Phase 2b Trial of MN-166 (Ibudilast) Involving 255 Progressive MS Patients

MediciNova, Inc., a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the ongoing clinical trial of MN-166 (ibudilast) in patients with progressive multiple sclerosis (progressive MS) has finished the randomization of 255 patients, exceeding the…

MediciNova Completes Enrollment for Phase 2b Study of Experimental Progressive Multiple Sclerosis Treatment

MediciNova, Inc., a publicly-traded biopharmaceutical company developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the National Institute of Neurological Disorders and Stroke (NINDS) notified the company of full enrollment of theirĀ ongoing clinical study evaluating ibudilastĀ (MN-166) for the treatment of progressive…

Phase III Study of Experimental MS Therapy Meets Primary Endpoint, Results to be Presented at ANN Meeting

MedDay, a French biotechnology company that studies treatments for nervous system disorders, including multiple sclerosis, announced that MD1003, a highly-concentrated biotin, is effective forĀ treatment of progressive multiple sclerosis, according to results from a recent Phase III trial. MD1003 may have two beneficial effects: 1) increasing myelin, the fatty nerve-insulating…

Progressive MS Pipeline Slowly Filling With New, Experimental Therapies

As the most common non-traumatic cause of disability in young people in the industrialized world, multiple sclerosis affects more than 2.5 million people globally. Those who suffer with the diseaseĀ are categorized into two types of multiple sclerosis patients: those with relapsing-remitting multiple sclerosis (RRMS) make up the majority of patients…

GeNeuro and Servier to Co-Develop Breakthrough Multiple Sclerosis Drug

Neurology and autoimmune therapeutics companyĀ GeNeuro SA has just announced the formation of a partnership with independent French pharmaceutical companyĀ ServierĀ for the co-development and marketing of GNbAC1 for Multiple Sclerosis (MS). It is the first humanized monocloncal antibody treatment formulated to address one of this disease’s causal factors, making it…

Glialogix Drug for Progressive MS Funded by National Multiple Sclerosis Society

San Francisco Bay Area-based Glialogix, Inc., a biopharmaceutical company that specializes in developing novel treatments for multiple sclerosis (MS), announced yesterday that they have closed aĀ Sponsored Research Agreement with Fast Forward, a non-profit organizationĀ that aims to accelerate MS treatment development.Ā Glialogix will receive funding for one of their…